실시간
FierceBiotechKurma closes €215M Europe-focused fund to spread across 20 biotechsFierceBiotechPfizer cans work on next-gen conjugate in cancer patientsThermo FisherThermo Fisher (TMO) Q1 2026 Earnings Transcript - The Motley FoolLonza NewsBanks kick off talks on Lone Star’s $1.75 billion Lonza unit debt - Bloomberg News - TradingViewPromega BlogThe Body Already KnowsLonza NewsBanks Kick Off Talks on Lone Star’s €1.5 Billion Lonza Unit Debt - Bloomberg.comThermo FisherThermo Fisher Scientific Q1 2026 Earnings Call: Complete Transcript - BenzingaThermo FisherThermo Fisher stock drops despite Q1 beat (update) (TMO:NYSE) - Seeking AlphaBioWorldAvacta Life Sciences patents FAP-activated camptothecin conjugatesBioWorldMabwell discloses new ADAM9-targeting ADCsBioWorldFosun Pharma discovers new PKMYT1 inhibitorsBioWorldChengdu Mfs Pharma synthesizes new compounds for pain
BioWorld 2026년 1월 22일

Corcept’s relacorilant could reach $2.1B ovarian cancer market

Corcept’s relacorilant could reach $2.1B ovarian cancer market

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.